US FDA accepts GSK's sBLA for Jemperli plus chemotherapy to expand treatment to all adult patients with primary advanced ...
GSK plc announced the US Food and Drug Administration (FDA) accepted the supplemental Biologics License Application (sBLA) for Jemperli (dostarlimab) in combination with standard-of-care chemotherapy (carboplatin and paclitaxel) to expand treatment to all …